Cargando…

Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group

OBJECTIVE: Patients with platinum-resistant ovarian cancer (PROC) have a high need for reliable prognostic markers. Since significance of primary platinum resistance (PPR) versus secondary platinum resistance (SPR) was identified for patients receiving anti-angiogenic therapy, it has not been confir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trillsch, Fabian, Mahner, Sven, Czogalla, Bastian, Rottmann, Miriam, Chekerov, Radoslav, Braicu, Elena Ioana, Oskay-Öczelik, Gülten, Wimberger, Pauline, Richter, Rolf, Sehouli, Jalid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039167/ https://www.ncbi.nlm.nih.gov/pubmed/33825355 http://dx.doi.org/10.3802/jgo.2021.32.e37

Ejemplares similares

Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients
por: Sehouli, Jalid, et al.
Publicado: (2021)

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)
por: Chekerov, Radoslav, et al.
Publicado: (2023)

Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial
por: Chekerov, Radoslav, et al.
Publicado: (2017)

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
por: Trillsch, Fabian, et al.
Publicado: (2013)

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO
por: Heublein, Sabine, et al.
Publicado: (2023)

Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany
por: Dimitrova, D., et al.
Publicado: (2021)

Results of a German wide survey towards current surgical approach in early stage cervical cancer NOGGO MONITOR 11
por: Armbrust, Robert, et al.
Publicado: (2021)

Can a morphological description of the peritoneal carcinomatosis in advanced ovarian cancer add prognostic information? Analysis of 1686 patients of the tumor bank ovarian cancer
por: Nasser, Sara, et al.
Publicado: (2022)

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
por: Woopen, Hannah, et al.
Publicado: (2014)

A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)
por: Sehouli, Jalid, et al.
Publicado: (2016)

H3K4me3 Is a Potential Mediator for Antiproliferative Effects of Calcitriol (1α,25(OH)2D3) in Ovarian Cancer Biology
por: Han, Nan, et al.
Publicado: (2020)

PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva
por: Czogalla, Bastian, et al.
Publicado: (2020)

The G-Protein-Coupled Estrogen Receptor (GPER) Regulates Trimethylation of Histone H3 at Lysine 4 and Represses Migration and Proliferation of Ovarian Cancer Cells In Vitro
por: Han, Nan, et al.
Publicado: (2021)

Protocol to optimize the biobanking of ovarian cancer organoids by accommodating patient-specific differences in stemness potential
por: Trillsch, Fabian, et al.
Publicado: (2023)

Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer
por: Kaltofen, Till, et al.
Publicado: (2020)

AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
por: Badmann, Susann, et al.
Publicado: (2022)

Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?
por: Fotopoulou, Christina, et al.
Publicado: (2012)

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
por: Runnebaum, Ingo B., et al.
Publicado: (2018)

Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer
por: Kulbe, Hagen, et al.
Publicado: (2019)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
por: Mahner, Sven, et al.
Publicado: (2012)

HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients
por: Braicu, Elena Ioana, et al.
Publicado: (2022)

Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 survey
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2022)

Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients
por: Czogalla, Bastian, et al.
Publicado: (2018)

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
por: Ray-Coquard, Isabelle, et al.
Publicado: (2019)

Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer Patients
por: Deuster, Eileen, et al.
Publicado: (2019)

Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy
por: Arsenic, Ruza, et al.
Publicado: (2015)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey
por: Woopen, Hannah, et al.
Publicado: (2023)

Subcellular Distribution of Thyroid Hormone Receptor Beta in Ovarian Cancer
por: Heublein, Sabine, et al.
Publicado: (2022)

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2012)

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
por: Willing, Eva-Maria, et al.
Publicado: (2023)

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Galectin-8 and -9 as prognostic factors for cervical cancer
por: Beyer, Susanne, et al.
Publicado: (2022)

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Stable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment
por: Hoffmann, Karen, et al.
Publicado: (2020)

Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer
por: Czogalla, Bastian, et al.
Publicado: (2020)

Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients
por: Ditsch, Nina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hb8sgcji9r1cqrgb6181ugmnjm